Compare Stocks: LRMR, JANX, CVAC, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$12.39 +2.9%	$17.13	$11.59 ▼ $35.34	$736.65M	2.44	989,817 shs	1.19 million shs
LRMR Larimar Therapeutics	$2.73 +1.5%	$2.97	$1.91 ▼ $6.42	$279.45M	0.73	1.56 million shs	1.16 million shs
MLTX MoonLake Immunotherapeutics	$13.51 +7.6%	$11.98	$9.46 ▼ $23.29	$1.07B	1.14	1.62 million shs	1.94 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-10.90%
JANX Janux Therapeutics	-5.64%	-32.44%	-34.53%	-27.77%	-56.36%
LRMR Larimar Therapeutics	+6.32%	+5.91%	+0.75%	-38.44%	-24.23%
MLTX MoonLake Immunotherapeutics	-0.48%	+7.35%	+16.08%	-27.10%	+16.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$12.39 +2.9%	$17.13	$11.59 ▼ $35.34	$736.65M	2.44	989,817 shs	1.19 million shs
LRMR Larimar Therapeutics	$2.73 +1.5%	$2.97	$1.91 ▼ $6.42	$279.45M	0.73	1.56 million shs	1.16 million shs
MLTX MoonLake Immunotherapeutics	$13.51 +7.6%	$11.98	$9.46 ▼ $23.29	$1.07B	1.14	1.62 million shs	1.94 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-10.90%
JANX Janux Therapeutics	-5.64%	-32.44%	-34.53%	-27.77%	-56.36%
LRMR Larimar Therapeutics	+6.32%	+5.91%	+0.75%	-38.44%	-24.23%
MLTX MoonLake Immunotherapeutics	-0.48%	+7.35%	+16.08%	-27.10%	+16.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
JANX Janux Therapeutics	2.67	Moderate Buy	$36.92	198.01% Upside
LRMR Larimar Therapeutics	3.00	Buy	$10.33	278.51% Upside
MLTX MoonLake Immunotherapeutics	2.57	Moderate Buy	$31.09	130.13% Upside

Current Analyst Ratings Breakdown

Latest LRMR, JANX, CVAC, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/6/2026	JANX Janux Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$26.00 ➝ $27.00
11/6/2026	JANX Janux Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$36.00 ➝ $40.00
11/6/2026	JANX Janux Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Underweight	$14.00 ➝ $15.00
11/6/2026	MLTX MoonLake Immunotherapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$57.00
10/19/2026	JANX Janux Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$50.00
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/14/2026	LRMR Larimar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$13.00

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
JANX Janux Therapeutics	$10M	75.80	N/A	N/A	$14.90 per share	0.83
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.59	N/A	N/A	N/A	N/A	-11.80%	-10.97%	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/11/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.67	N/A	N/A	N/A	N/A	-79.95%	-56.40%	N/A

Latest LRMR, JANX, CVAC, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	LRMR Larimar Therapeutics	-$0.3501	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	JANX Janux Therapeutics	-$0.4735	-$0.34	+$0.1335	-$0.34	$8.03 million	$9.29 million
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.8326	-$0.93	-$0.0974	-$0.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
JANX Janux Therapeutics	N/A	17.68	16.35
LRMR Larimar Therapeutics	N/A	4.70	4.70
MLTX MoonLake Immunotherapeutics	0.26	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
JANX Janux Therapeutics	75.39%
LRMR Larimar Therapeutics	91.92%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
JANX Janux Therapeutics	7.90%
LRMR Larimar Therapeutics	4.00%
MLTX MoonLake Immunotherapeutics	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
JANX Janux Therapeutics	114	61.18 million	56.35 million	Optionable
LRMR Larimar Therapeutics	71	103.88 million	99.73 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable

LRMR, JANX, CVAC, and MLTX Headlines

Recent News About These Companies

MLTX stock climbs on optimism ahead of FDA acceptance deadline for lead drug filing

3 hours ago | msn.com

Research Analysts Issue Forecasts for MLTX FY2026 Earnings

November 11 at 7:12 AM | marketbeat.com

Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?

November 11 at 4:17 AM | finance.yahoo.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Breaks Above 50 Day Moving Average - Here's What Happened

November 10 at 4:59 AM | marketbeat.com

MoonLake Immunotherapeutics (MLTX) Gets a Buy from Guggenheim

November 6, 2026 | theglobeandmail.com

Chardan Capital Initiates Coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX)

November 6, 2026 | marketbeat.com

MoonLake Reports Wider Q3 Loss At $79 Mln Following BLA Submission For Sonelokimab

November 5, 2026 | rttnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

November 4, 2026 | marketbeat.com

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

November 4, 2026 | globenewswire.com

MoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on Wednesday

November 3, 2026 | americanbankingnews.com

RBC Capital Sticks to Their Hold Rating for MoonLake Immunotherapeutics (MLTX)

October 31, 2026 | theglobeandmail.com

MoonLake Immunotherapeutics (MLTX) Expected to Announce Quarterly Earnings on Wednesday

October 28, 2026 | marketbeat.com

MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds

October 25, 2026 | finance.yahoo.com

MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions

October 24, 2026 | finance.yahoo.com

MoonLake Immunotherapeutics (MLTX) - What Are Investment Firms Saying About This Stock?

October 24, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6.4% - Here's Why

October 23, 2026 | marketbeat.com

What's Going On with MoonLake Immunotherapeutics Stock on Thursday?

October 22, 2026 | benzinga.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Sees Heavy Call Option Buying

October 21, 2026 | marketbeat.com

MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains

October 20, 2026 | seekingalpha.com

MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says

October 18, 2026 | msn.com

MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says

October 16, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, JANX, CVAC, and MLTX Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 11/9/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Janux Therapeutics NASDAQ:JANX

$12.39 +0.35 (+2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$12.40 +0.01 (+0.12%)

As of 07:50 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Larimar Therapeutics NASDAQ:LRMR

$2.73 +0.04 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.83 +0.10 (+3.77%)

As of 07:58 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

MoonLake Immunotherapeutics NASDAQ:MLTX

$13.51 +0.95 (+7.56%)

Closing price 04:00 PM Eastern

Extended Trading

$13.52 +0.02 (+0.11%)

As of 07:49 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, JANX, CVAC, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, JANX, CVAC, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, JANX, CVAC, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, JANX, CVAC, and MLTX Company Descriptions

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

Larimar Therapeutics NASDAQ:LRMR

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LRMR, JANX, CVAC, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LRMR, JANX, CVAC, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LRMR, JANX, CVAC, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, JANX, CVAC, and MLTX Company Descriptions

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

Larimar Therapeutics NASDAQ:LRMR

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools